Phase I trial patients experienced shrinkage of brain tumors and extended survival rates beyond the standard prognosis of one ...

The investigational drug demonstrated robust STAT6 degradation in blood and skin that was well tolerated and safe in healthy volunteers.

A new study found that aged neurons have defects in key proteins that make them vulnerable to molecular stress and neurodegenerative damage.

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.

Bora Pharmaceuticals also offers lyophilization, terminal sterilization, analytical, stability, and packaging and serialization services.

Therapeutic plasma exchange combined with intravenous immunoglobulin reduced biological age on average by 2.6 years, as ...

A decades-old TB vaccine turned cancer therapy may unlock new immunotherapies by reprogramming immune cell development in the ...

Replacing PEG with PCB in lipid nanoparticles led to potent mRNA vaccines that avoided unwanted immune responses.

The IDMO Smart Factory initiative has the potential to help advance the development and approval of CAR-T therapeutics in ...

Mouse models treated with the sleep aid lemborexant had less brain damage compared to controls and mice that received a ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

The latest imaging method from the Broad Institute uncovers structural disruptions in the nucleus associated with progeria at ...